Associate
Chartered Patent Attorney
European Patent Attorney
UK Design Attorney
BSc Biochemistry, University College London
MSc Cellular Therapy from Bench to Market, King’s College London
Thank you
Matt is an Associate in the Life Sciences and Chemistry team. He has an academic background in biochemistry and advanced therapies, as well as industry experience in the cell and gene therapy field. Matt has advised companies in technology areas such as antibodies, biological materials, biotech, cell therapies, CRISPR, cultivated meat, engineered plants, gene therapies, nanotechnologies, medical devices, medtech, small molecules, synthetic biology, as well as viral and non-viral gene editing. Working across patents, designs, plant variety rights, and biological deposits, his broad experience allows him to assist a range of companies from start-ups to major multinationals.
Matt particularly enjoys working closely with clients to understand not only the detail behind their technology, but the business needs behind their intellectual property. He has experience not only in drafting and prosecuting patents, but also in freedom to operate, patentability, and due diligence work. Matt has also worked on contentious matters before the Board of Appeal, and has experience managing broad global portfolios.
Matt qualified as a UK and European Patent Attorney in 2024. Before joining Keltie in 2022, he spent three years training at another leading patent law firm. Prior to joining the profession, he worked in the lab at the Cell and Gene Therapy Catapult gaining experience in ddPCR, cell culture, non-viral gene editing techniques, flow cytometry, as well as upstream and downstream processing of AAV (viral vector) for gene therapy applications. His academic background includes a BSc in Biochemistry from UCL and an MSc entitled ‘Cellular Therapy from Bench to Market’ - a course which blended biology and business to explore the science, regulation and routes to market underpinning advanced therapies.
02.04.2024
Patents, plausibility and data: one year on from G 2/21On 23 March 2023, the European Patent Office (EPO) Enlarged Board of Appeal (EBA) published its decision in case G 2/21, concerning plausibility in patent applications. The decision provided useful guidance on how much data needs to be disclosed in a patent application to overcome objections based on the grounds of lack of inventive step and insufficiency. One year on, we take a look at how the EPO has been applying this standard in the life sciences field.
21.09.2023
Deadline approaches for the EPO’s “10-day rule”The “10-day” rule, which determines how the response deadlines to certain European Patent Office (EPO) communications are calculated, is to be abandoned from 1 November 2023.
OtherLess related knowledge
Thank you
